STOCK TITAN

Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2023 Results and Participation in Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Shockwave Medical, Inc. will report financial results for the third quarter 2023 after market close on November 6, 2023. Company management will host a conference call and present at the 5th Annual Wolfe Research Healthcare Conference on November 15, 2023.
Positive
  • None.
Negative
  • None.

SANTA CLARA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the third quarter 2023 after market close on Monday, November 6, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

On Wednesday, November 15, 2023, at 8:45 a.m. Eastern Time, Shockwave Medical management is scheduled to present at the 5th Annual Wolfe Research Healthcare Conference, which is taking place from Tuesday, November 14 - Wednesday, November 15, 2023, in New York, NY.

Interested parties may access live and archived webcasts of these events on the "Investors" section of the company’s website at https://ir.shockwavemedical.com. Investors interested in dialing in to the third quarter 2023 Shockwave Medical earnings conference call on Monday November 6, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time may do so by dialing 877-704-4453 for domestic callers or 201-389-0920 for international callers, using conference ID: 13737257.

About Shockwave Medical, Inc.

Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
investors@shockwavemedical.com


FAQ

When will Shockwave Medical report its financial results for Q3 2023?

Shockwave Medical will report its financial results for Q3 2023 after market close on November 6, 2023.

What conference will Shockwave Medical present at on November 15, 2023?

Shockwave Medical will present at the 5th Annual Wolfe Research Healthcare Conference on November 15, 2023.

Where can I access webcasts of these events?

You can access live and archived webcasts of these events on the 'Investors' section of Shockwave Medical's website at https://ir.shockwavemedical.com.

How can I participate in the conference call for the Q3 2023 earnings?

To participate in the conference call for the Q3 2023 earnings, dial 877-704-4453 for domestic callers or 201-389-0920 for international callers, using conference ID: 13737257.

Shockwave Medical, Inc.

NASDAQ:SWAV

SWAV Rankings

SWAV Latest News

SWAV Stock Data

12.39B
36.82M
1.27%
95.6%
5.43%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SANTA CLARA

About SWAV

shockwave medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. inspired by 30-years of safety and efficacy in kidney stone treatment, our lithoplasty® family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. lithoplasty devices use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. an integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. in peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, lithoplasty technology demonstrated safety and consistent procedure success with low procedural complications. the technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatmen